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Abstract 
Fibromyalgia, characterised by persistent pain, sleep disturbance, fatigue and cognitive 
dysfunction, is a central sensitivity syndrome that also involves abnormality in peripheral 
generators and in the hypothalamic pituitary adrenal axis. Heterogeneity of clinical 
expression of fibromyalgia with a multifactorial aetiology has made the development of 
effective therapeutic strategies challenging. Non-restorative sleep associated with poor sleep 
quality is a characteristic of fibromyalgia which is linked to symptom severity. A relationship 
between sleep disorder and central sensitization could be a possible factor involved in 
development, exacerbation and/or maintenance of fibromyalgia. Association between 
disordered sleep and the risk of fibromyalgia suggests that limiting sleep problems would 
reduce the incidence of the condition. Therapeutic approaches with treatments that 
consolidate or deepen sleep may be preferential to improve sleep in patients with 
fibromyalgia. Thus, disordered sleep appears fundamental to the pathophysiology of 
fibromyalgia and as such the risk of sleep disturbances needs to be proactively assessed and 
when identified in this patient group be actively managed to improve health outcomes for 
patients with fibromyalgia. 
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1. Introduction 
Fibromyalgia is characterised by persistent pain, fatigue, sleep disturbance and cognitive 
dysfunction (i.e. attentional capacity and memory) with disorder of central pain processing 
producing heightened responses to painful stimuli (hyperalgesia) and painful responses to non-
painful stimuli (allodynia) dominating the condition *1, 2+. Co-morbidities of fibromyalgia include 
psychiatric conditions such as depression and anxiety *1, 2+. Classification of fibromyalgia was 
originally based on the American College of Rheumatology (ACR) 1990 criteria of widespread pain 
(for at least 3 months) and pain in 11 of 18 tender point sites *3+. Revision of the criteria in 2010 
introduced assessment of the range of symptoms by determination of somatic symptom severity 
(i.e. sleep disturbance, cognitive dysfunction and fatigue) and widespread pain, avoiding reliance 
on tender points with further revision in 2016 to limit potential misclassification and introduce a 
fibromyalgia symptom scale *4, 5+. Worldwide prevalence, based on application of ACR 1990 
criteria, of 0.4–8% of the population has been reported, with fibromyalgia being seven times more 
common in females than males *6+.  
The pathophysiology of fibromyalgia involves enhanced neuronal excitability, related to central 
(CS) and peripheral sensitization, presenting amplified responses of the central nervous system 
(CNS) to peripheral input *2+. Peripheral sensory generators contributing to this heightened activity 
of the CNS, include nerve pathologies, neuroinflammation, skeletal muscle abnormalities and 
ischaemia *7, 8+. Systemic stress-related events linked to alterations in the hypothalamic pituitary 
adrenal axis (HPA), autonomic nervous system and cardiovascular system have also been reported 
to be underlying or enhancing the symptoms of fibromyalgia *2, 7+. In addition to neuronal 
sensitization and neuroendocrine dysfunction, oxidative stress, immunological factors and genetics 
have also been linked with the pathophysiology. The characteristic spectrum of symptoms of 
fibromyalgia however cannot be accounted for by any of these factors in isolation. 
Altered neurotransmitter functioning and neuroplasticity, consistent with an enhanced 
excitation and reduced inhibition within the CNS leading to augmented sensory processing, has 
been suggested to contribute to the CS in fibromyalgia *7+. Raised levels of glutamine (2-fold), 
nerve growth factor (4-fold), brain-derived neurotrophic factor (BDNF, 2 to 4-fold), substance P (2 
to 3 fold) and endogenous opioids (3 to 4-fold) are observed in the cerebrospinal fluid (CSF) of 
people with fibromyalgia compared to healthy subjects *2, 9-11+. In contrast, in people with 
fibromyalgia lower CSF levels have been reported of the main metabolites of serotonin, 5-
hydroxyindoleacetic acid (5-HIAA), and noradrenaline, 3-methoxy-4-hydroxyphenylglycol (MHPG), 
and blood levels of serotonin and L-tryptophan *2, 9+.  
The combination of pharmacological and non-pharmacological therapeutic approaches is 
required for the management of fibromyalgia with the approach to drug therapies being empiric 
with a focus towards individual symptoms, primarily pain *1, 4+. Thus, a primary aim of many of the 
pharmacological treatments is lowering levels of pronociceptive excitatory neurotransmission 
and/or increasing antinociceptive inhibitory neurotransmission in the CNS. Current therapeutic 
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options for fibromyalgia are drugs that raise serotonin and noradrenaline levels in the CNS (e.g. 
tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors) or target voltage-gated 
calcium channel subunits (e.g. gabapentin and pregabalin) *1, 4+. The heterogeneity of clinical 
expression of the spectrum of symptoms of fibromyalgia in combination of a multifactorial 
aetiology has made the development of effective therapeutic strategies challenging.  
The aim of this article is to consider the relationship of fibromyalgia and sleep, with respect to 
involvement in the pathophysiology or as a treatment approach of the condition. MEDLINE 
database, Web of Science and Google Scholar were used to identify relevant studies and 
publications up to August 2019 using the terms ‘sleep’ and ‘fibromyalgia’. 
2. Sleep Disturbances in Fibromyalgia 
Approximately 90% of patients with fibromyalgia experience sleep disturbance with poor sleep 
quality strongly associated with symptom severity *12-15+. Complaints concerning sleep include 
superficial, fragmented and non-restorative sleep, and restless leg syndrome followed by early 
awakening and morning fatigue *16, 17+. Although sleep quality is poor leading to the enhanced 
pain and fatigue with patients waking with stiffness and reduced physical functioning, often 
quantity of sleep of up to 8 hours is experienced *18, 19+. Patients with fibromyalgia report 
difficulty falling asleep, significantly more night -time awakenings, extended stage 1 sleep, and 
diminished slow wave sleep during non-rapid eye movement sleep *20-22+. Slow wave sleep is 
essential to feeling refreshed upon awakening, thus alterations in patients with fibromyalgia will be 
associated with unrefreshing sleep and arousal or awakening states *23+.  
Subnormal growth hormone secretion and low levels of somatomedin C have been observed in 
some patients with fibromyalgia *24, 25+. A loss of growth hormone secretion during slow wave 
sleep may be linked to abnormalities in dorsal medial nucleus of the thalamus *26+. Abnormal 
thalamic activity and a lower stimulus threshold for the activation of the pain pathway are 
manifestations of fibromyalgia at the neural level *27, 28+. Growth hormone and somatomedin C 
are necessary for the repair of microtrauma; sleep disturbances associated with fibromyalgia may 
impair the healing of muscle tissue damage which will continue to transmit sensory stimuli to the 
CNS maintaining the perception of muscle pain. The enhanced pain will contribute to the sleep 
disturbance which will maintain the inadequate muscle tissue repair.  
Heterogeneity has been observed across studies of sleep in fibromyalgia, which may be related 
to age, body mass index (BMI), tender points, time since diagnosis and assessment methodology 
*21, 22+. Sleep difficulties in fibromyalgia appear to be greater when reported subjectively, e.g. 
using Pittsburgh Sleep Quality Index (PSQI), than when assessed objectively, e.g. using 
polysomnography or actigraphic devices, which may be a consequence of perception and the 
possibility of catastrophizing being common with this condition *22+. Subjective methods of sleep 
assessment can include instruments such as the PSQI, the Fibromyalgia Impact Questionnaire and 
written or electronic sleep diaries which are reliant on self-report and are the involved in the 
evaluation and treatment of sleep complaints within the clinical setting. Studies have suggested 
subjective report of sleep quality exhibited a relationship to fibromyalgia symptoms, which was 
not observed with objective sleep data *29, 30+. Subjective assessment is dependent upon 
accurate recall and perception of sleep quality rather than evaluation of sleep architecture, which 
will be influenced by personal and environmental factors (eg fatigue, poor mood) at the time. 
OBM Neurobiology 2020; 4(1), doi:10.21926/obm.neurobiol .2001049 
 
Page 4/16 
Consequently, the level of presentation of fibromyalgia symptoms may lead to greater attribution 
to sleep disturbance. Thus, therapeutic approaches that target perception (e.g. cognitive-
behavioural approach) rather than sleep architecture (e.g. medication) may provide preferable 
outcomes. Although it would appear preferable to confirm sleep complaints with an objective 
method, this may not be feasible in a clinical setting. In addition, actigraphic devices, which 
monitor movement, would record a motionless person as asleep and could misrepresent the 
bedtime habits of the patient with fibromyalgia. 
3. Risk Factors of Fibromyalgia and Sleep Disturbance 
Persistent widespread pain being a risk factor of disordered sleep, recorded by 
polysomnographic, has been reported in studies of patients with fibromyalgia *21, 31+. Patterns of 
sleep discontinuity and lower sleep efficiency are consistent with the persistent pain being 
associated with heightened states of arousal during sleep *32+. In addition, disordered sleep and 
decreased rapid eye movement (REM) sleep is associated with increases in the risk of fibromyalgia 
symptoms, pain perception and widespread pain *15, 33-37+. More sleep interruption and 
movement at night with increased sleeping and lower levels of activity during the day have been 
observed in patients with fibromyalgia when depressed *38+. Depression levels in patients with 
fibromyalgia have also been suggested to be predictors of subjective sleep quality *21+. In this 
patient group depression appears to be exacerbated by and contribute to sleep disturbance *39+. 
The tendency to experience depressive symptoms, as with persistent pain, correlates with 
hyperarousal indices during sleep leading to sleep complaints *40+.  
Patients with fibromyalgia have a high prevalence of overweight and obesity which is associated 
with a higher number of sleep disturbances and painful regions *14, 41, 42+. The prevalence of 
overweight in patients may contribute to additional sleep disorders such as sleep apnea, 
inspiratory airflow limitation with arousals and obstructive sleep apnea which can be common in 
patients with fibromyalgia *43-45+. Alleviation of symptoms has been reported following weight 
loss in patients with fibromyalgia, whilst reduction of the risk of fibromyalgia is associated with 
regular physical activity *46-48+. In patients with obstructive sleep apnea treatment with 
continuous positive airway pressure exhibited beneficial in patients with fibromyalgia *49+. 
Lifestyle factors have therefore been proposed to influence the association between insomnia 
symptoms and risk of fibromyalgia *50+. Self-reported physical activity intensity levels have been 
associated with sleep quality in women with fibromyalgia *51+. Higher physical activity levels and 
lower sedentary time are associated with reduced symptoms in patients  with fibromyalgia *52, 53+. 
In a cross-sectional study of women with fibromyalgia, more sedentary time was associated with 
significantly worse subjective sleep quality, sleep duration, sleep disturbance and daytime 
dysfunction assessed by the PSQI *54+. Better subjective sleep quality, sleep latency, sleep 
medication and daytime dysfunction were correlated with physical activity, whether light, 
moderate or moderate-to-vigorous. Thus, women with fibromyalgia who engage more physical 
activity (recommendations of 150 minutes/week of moderate -to-vigorous physical activity in 
bouts > 10 minutes) and present less sedentary time, pain and anxiety appear to have improved 
night-time sleep and feel less sleepy during the day. In fibromyalgia there is however discordance 
between self-reported assessments and objective measurements of physical activity associated 
with catastrophizing cognitions *55+. Consequently, misleading information for this patient 
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population can be generated with physical activity questionnaires thus the use of objective 
measure, such as accelerometry, would be the preferred approach *56, 57+. 
Patients with fibromyalgia have been reported to have attenuated parasympathetic activity, 
assessed by heart rate variability, during non-REM stage 2 sleep and REM sleep which constituted 
about 80% of total sleep time *58+. The sympathetic autonomic nervous system is stimulated 
during physical activity, however after physical activity the sympathetic tone will decrease,  and 
parasympathetic activity become dominant *59, 60+. The participation in physical activity will lead 
to the physiological responses of a decrease in heart rate and blood pressure with an anxiolytic 
effect which will facilitate better sleep quality. Non-restorative sleep associated with fibromyalgia 
may therefore be related to the altered autonomic nervous system (ANS) activity. Studies have 
demonstrated that aerobic and aquatic exercise, and resistance training, activities that modulate 
the ANS, have significantly decreased sleep disturbance and improved sleep quality in patients 
with fibromyalgia *61-63+.  
An association between pain severity and cognitive performance has been demonstrated which 
also appears to be influenced by sleep in individuals with fibromyalgia *64+. Thus, poor sleep 
quality is associated with pain severity and poor cognitive performance, and due to reciprocal 
relationships pain leads through an effect on sleep quality to impaired sustained attention *65+. 
Improved sleep quality would therefore offset the detrimental effects of pain on sustained 
attention. In addition to lower sustained attention, impaired performance speed in complex 
cognitive tasks is associated with low sleep quality in patients with fibromyalgia *66+. Intense pain 
experienced by patients with fibromyalgia have been associated with poor learning and memory 
performance, attention function and psychomotor processing speed *67-69+. 
4. Current Treatments for Fibromyalgia 
Current treatment options of fibromyalgia focus on symptom-based management to improve 
quality of life with combination of pharmacological and non -pharmacological treatment to achieve 
the best outcome for the patient *1, 4+. Although the primary objective is often pain control, 
recommended treatment approaches of fibromyalgia produce some effect on sleep qual ity (Table 
1). Treatments that improve sleep quality rather than quantity would decrease pain and fatigue 
whilst enhancing functioning and quality of life.  
Table 1 Effect of pharmacological treatments on s leep disorder in fibromyalgia. FIQ 
fibromyalgia impact questionnaire, GABA gamma amino butyric acid. 
Treatment Class Outcomes Reference 
Amitriptyline Tricyclic antidepressant Improved self-assessment of 
sleep quality using the FIQ scale 
78 
Cyclobenzaprine Tricyclic muscle relaxant Improved sleep quality, 
increased total sleep time, 
increased number of nights of 
restorative sleep. 
82-86 
Pregabalin Gabapentanoid Patients’ report of improved 
sleep quality, decreased sleep 
87-90 
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latency and enhanced slow-
wave sleep. 
Polysomnography recorded 
increase in sleep duration and 
slow wave sleep with a decrease 
in wake after sleep bouts. 
Gabapentin Gabapentanoid Improved sleep quantity and 
quality assessed by Medical 
Outcome Sleep Questionnaire. 
91 
Zolpidem GABAA receptor agonist Reduced time to fall asleep, 
increased sleep time, reduced 
awakenings and overall 
improvement in sleep. 
93 
Sodium Oxybate Gamma-
aminohydroxybutyrate and 
gamma-hydroxybutyrate 
receptor agonist 
Facilitating slow-wave sleep and 
reducing wake periods after 
sleep onset. 
96-99 
Melatonin Melatonergic receptor 
agonist 
Decreased sleep latency and 
total nocturnal activity. 
Increased sleep efficiency, 
actual sleep time and assumed 
sleep. 
109-114 
4.1 Non-Pharmacological Treatments 
As fibromyalgia is characterised with bad sleep hygiene and sleep fragmentation patients would 
benefit from behavioural interventions such as cognitive-behavioural therapy for sleep disturbance 
rather than pharmacological therapies focused to pain linked to sleep disruption. Cognitive 
behavioural therapy in patients with fibromyalgia improves subjective sleep, pain catastrophizing, 
anxiety and depression *70+. In a randomized controlled trial cognitive behavioural therapy for 
insomnia (CBT-I), involving sleep education and sleep hygiene training, and cognitive behavioural 
therapy for pain (CBT-P), involving pain education and adaptive techniques training, both led to 
improvements in self-reported sleep (wake after sleep onset, sleep efficiency, sleep quality) in 
patients with fibromyalgia *71+. The CBT-I achieved greater outcomes that persisted at 6 months. 
Interestingly neither treatment demonstrated improvement on objective sleep (actigraphy and 
polysomnography), pain or mood outcomes. Atrophy of cortical gray matter in regions such as the 
amygdala, anterior cingulate cortex, insula and thalamus has been reported in patients with 
fibromyalgia *72-74+. Individuals with fibromyalgia in an 8-week study receiving CBT-I 
demonstrated increases in cortical thickness following treatment and those receiving CBT-P 
showed less gray matter atrophy than untreated control subjects *75+. Thus, behavioural 
treatments for sleep disorder in fibromyalgia which demonstrated restorative benefit of 
consolidated sleep may be associated with cortical plasticity.  
Balneotherapy has been used as a treatment in patients with fibromyalgia, with the passive 
immersion in hot baths (36 :C) benefiting pain and sleep quality *76+. In a study of sleep patterns 
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of patients with fibromyalgia using polysomnography, passive body heating decreased sleep onset 
time, REM sleep latency and the number of awakenings with improvement in sleep efficiency and 
slow wave sleep *77+. The likelihood that the reported effects are the result of passive body 
heating on sleep independent of the fibromyalgia cannot be ignored. As sleep disturbance can act 
as a trigger of fibromyalgia symptoms, passive body heating may thereby attenuate the expression 
of the condition.  
4.2 Pharmacological Treatments 
Antidepressant drugs, such as amitriptyline, duloxetine and milnacipran, are often used as a 
treatment of fibromyalgia *1, 4+. Low-dose amitriptyline (10-100 mg/day), a tricyclic 
antidepressant, has been shown to moderately improve pain, fatigue and sleep, with a lack of 
effect on mood *4, 78+. In contrast the serotonin and noradrenaline reuptake inhibitors, 
milnacipran (up to 200 mg/day) and duloxetine (up to 120 mg/day), failed to significantly improve 
parameters of sleep, studied by polysomnography, in patients with fibromyalgia *79-81+. 
Cyclobenzaprine, a tricyclic muscle relaxant chemically related to amitriptyline, (10 mg/day) has 
been reported to improve sleep quality, increase total sleep time and reduce pain in patients with 
fibromyalgia *82-85+. In a double-blind placebo-controlled study with very low-dose 
cyclobenzaprine (1-4 mg/day), polysomnography showed an increased number of nights of 
restorative sleep *86+. 
The gabapentanoids, pregabalin and gabapentin, exhibit efficacy as treatments of fibromyalgia 
*1, 4+. In randomised control trials with patients with fibromyalgia, pregabalin (300 and 450 
mg/day) improved sleep quality based on patients’ report with a decrease in sleep latency and 
enhancement of slow-wave sleep and reduced pain, anxiety and depression *87-89+. 
Polysomnography was used in a randomised placebo-controlled crossover trial to objectively study 
the effect of pregabalin (150-450 mg/day) on disturbed sleep in patients with fibromyalgia *90+. 
Sleep duration was significantly increased and wake after sleep bouts were significant decreased 
associated with slow wave sleep, consistent with pregabalin increasing deep sleep and improving 
sleep quality. Improved sleep quantity and quality assessed by Medical Outcome Sleep 
Questionnaire was observed during 12 weeks of an open-label study of gabapentin in patients with 
fibromyalgia *91+. 
The sedative hypnotics, zolpidem and zopiclone, enhance the inhibitory properties of GABA due 
to actions on GABAA receptors leading to increased slow wave sleep *92+. In double-blind 
randomized placebo-controlled trials of zolpidem (10 mg/day) patients with fibromyalgia 
demonstrated reduced time to fall asleep, increased sleep time, reduced awakenings and overall 
improvement in sleep *93+. In contrast zopiclone failed to modify self-assessed sleep architecture 
in patients with fibromyalgia, *94+. These medications are commonly prescribed for the treatment 
of insomnia, a complaint not characteristic of fibromyalgia where disturbed sleep with frequent 
awakening is typical in this patient group. 
Sodium oxybate is an agonist of gamma-aminohydroxybutyrate and gamma-hydroxybutyrate 
receptors which is used in the treatment of excessive daytime sleepiness associated with 
narcolepsy *95+. In randomized placebo-controlled trials sodium oyxbate (4.5 or 6.0 g per night) 
reduced sleep disturbance by facilitating slow-wave sleep and reducing wake periods after sleep 
onset and reduced fatigue in patients with fibromyalgia *96-99+. Although there was a reduction in 
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pain this was not considered to be a direct effect, but a consequence of the improvements on 
sleep. These findings with sodium oxybate further support the sleep dysfunction in fibromyalgia 
having an important role in abnormal pain processing. 
Melatonin is a neurohormone synthesized mainly by the pineal gland from tryptophan and 
serotonin that plays in a role in the regulation of the 24-hour pattern of bodily functions *100,101+. 
The symptoms of fibromyalgia being associated with dysregulation of the HPA and autonomic 
nervous systems has led to the proposal of involvement of melatonin and the melatonergic system 
in the pathophysiology of fibromyalgia. A decrease in melatonin synthesis due to low levels of 
tryptophan and serotonin as observed in patients with fibromyalgia may contribute to the 
characteristic symptoms of pain and abnormal sleeping patterns *2, 9+. Conflicting observations of 
the levels of melatonin in patients with fibromyalgia have however been reported with both 
abnormal levels and levels not different relative to health controls *102-108+. Interest from a 
potential therapeutic perspective as a treatment of fibromyalgia has been stimulated due to the 
chronotropic, analgesic and anxiolytic properties of melatonin. The therapeutic use of melatonin 
has been investigated in several studies of patients with fibromyalgia which included open-pilot, 
double-blind randomized controlled trial (RCT) and longitudinal placebo-controlled design *109-
114+. In longitudinal placebo-controlled studies in patients with fibromyalgia, melatonin (6 – 15 
mg/day) improved the symptoms related to sleep quality, fatigue and pain leading to enhanced 
quality of life *113, 114+. Objective sleep quality, assessed by actigraphy, and subjective sleep 
quality, assessed by the PSQI, was improved by 10 days of melatonin treatment (6 – 15 mg daily) to 
patients with fibromyalgia *114+. Administration of the higher doses of melatonin (12 and 15 mg 
daily) decreased sleep latency and total nocturnal activity, and increased sleep efficiency, actual 
sleep time and assumed sleep. Improvements in the symptoms of fibromyalgia in patients 
following melatonin administration are consistent with regulation of circadian rhythm 
synchronisation and a direct effect on pain pathways. 
5. Conclusion 
Non-restorative sleep associated with poor sleep quality is a characteristic of fibromyalgia 
which is linked to symptom severity. Biochemical abnormalities within the thalamus and related 
abnormal thalamic activity may be responsible for the sleep patterns in patients with fibromyalgia. 
Risk factors of fibromyalgia, including persistent pain, depression, cognitive performance, 
overweight and physical activity, appear to exhibit a reciprocal relationship with disordered sleep 
and could be predictors of subjective sleep quality. The observed association between disordered 
sleep and the risk of fibromyalgia suggests that the incidence of fibromyalgia would be reduced by 
limiting sleep problems. A relationship between sleep disorder and central sensitization could be a 
possible factor involved in development, exacerbation and/or maintenance of fibromyalgia *115+. 
These observations will provide clues for therapeutic approaches with treatments that 
consolidate or deepen sleep may be more preferential to improve sleep in patients with 
fibromyalgia in comparison to interventions whose primary mode of activity is to induce sleep. 
During the development of new treatments, polysomnography evidence demonstrating an effect 
on sleep architecturein patients with fibromyalgia is essential. The dosing regimes of drugs, tested 
as treatments of fibromyalgia, are often based on the pharmacokinetics adopted from use in the 
management of other conditions (e.g. anxiety, depression and epilepsy). Application of therapeutic 
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interventions more specific to fibromyalgia and the characteristic symptoms , including sleep 
disorder, may offer better effectiveness. 
Thus, evidence is consistent with disordered sleep being fundamental to the pathophysiology of 
fibromyalgia and improvement of sleep quality can reduce other symptoms, such as pain, in 
individuals. The risk of sleep disturbances needs to be proactively assessed and when identified in 
this patient group be actively managed. Multidisciplinary interventions developed to manage, at 
least sleep quality and pain, would improve health outcomes for patients with fibromyalgia. 
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